| [1] |
李吉, 陈杨, 张茂镕, 等. 中国常见消化系统恶性肿瘤伤残调整寿命年归因于人口老龄化的比例分析和趋势预测[J]. 实用肿瘤学杂志, 2025, 39(5): 372-380.
|
| [2] |
Piccinno G, Thompson KN, Manghi P, et al. Pooled analysis of 3,741 stool metagenomes from 18 cohorts for cross-stage and strain-level reproducible microbial biomarkers of colorectal cancer[J]. Nat Med, 2025, 31(7): 2416-2429.
|
| [3] |
陈劲松, 陈锦旭, 王荣昌. 肠道菌群在结直肠癌中的作用[J/OL]. 中华普通外科学文献(电子版), 2023, 17(3): 169-172.
|
| [4] |
宋德心, 王伟东, 高瑞祺, 等. 肠道菌群在结直肠癌发生发展和诊断治疗中的作用研究进展[J]. 中国普通外科杂志, 2022, 31(4): 527-536.
|
| [5] |
Elkrief A, Pidgeon R, Maleki Vareki S, et al. The gut microbiome as a target in cancer immunotherapy: opportunities and challenges for drug development[J]. Nat Rev Drug Discov, 2025, 24(9): 685-704.
|
| [6] |
邵雨琪, 洪洁. 肠道菌群和结直肠癌发生发展及治疗的研究进展[J]. 中国肿瘤临床, 2024, 51(17): 881-887.
|
| [7] |
张威, 姜可伟. 肠道菌群在结直肠癌发生发展及治疗中的作用[J]. 中华胃肠外科杂志, 2020, 23(5): 516-520.
|
| [8] |
Simpson RC. Shanahan ER, Scolyer RA, et al. Towards modulating the gut microbiota to enhance the efficacy of immune-checkpoint inhibitors[J]. Nat Rev Clin Oncol, 2023, 20(10): 697-715.
|
| [9] |
Chen C, Su Q, Zi M, et al. Harnessing gut microbiota for colorectal cancer therapy: from clinical insights to therapeutic innovations[J]. NPJ Biofilms Microbiomes, 2025, 11(1): 190.
|
| [10] |
Gan AW, Kang X, Goh SS, et al. Recent advances in the encapsulation of probiotics as functional foods for colorectal cancer prevention[J]. J Funct Foods, 2025, 128: 106804.
|
| [11] |
Yang Y, An Y, Dong Y, et al. Fecal microbiota transplantation: no longer cinderella in tumour immunotherapy[J]. EBioMedicine, 2024, 100: 104967.
|
| [12] |
Feitelson MA, Arzumanyan A, Medhat A, et al. Short-chain fatty acids in cancer pathogenesis[J]. Cancer Metastasis Rev, 2023, 42(3): 677-698.
|
| [13] |
Niekamp P, Kim CH. Microbial metabolite dysbiosis and colorectal cancer[J]. Gut Liver, 2023, 17(2): 190-203.
|
| [14] |
Ou S, Wang H, Tao Y, et al. Fusobacterium nucleatum and colorectal cancer: From phenomenon to mechanism[J]. Front Cell Infect Microbiol, 2022, 12: 1020583.
|
| [15] |
Zepeda-Rivera M, Minot SS, Bouzek H, et al. A distinct Fusobacterium nucleatum clade dominates the colorectal cancer niche[J]. Nature, 2024, 628(8007): 424-432.
|
| [16] |
Purcell RV, Permain J, Keenan JI. Enterotoxigenic bacteroides fragilis activates IL-8 expression through Stat3 in colorectal cancer cells[J]. Gut Pathog, 2022, 14(1): 16.
|
| [17] |
Van Dingenen L, Segers C, Wouters S, et al. Dissecting the role of the gut microbiome and fecal microbiota transplantation in radio- and immunotherapy treatment of colorectal cancer[J]. Front Cell Infect Microbiol, 2023, 13: 1298264.
|
| [18] |
Moniri NH, Farah Q. Short-chain free-fatty acid G protein-coupled receptors in colon cancer: a review[J]. Biochem Pharmacol, 2021, 186: 114483.
|
| [19] |
Gu C, Sha G, Zeng B, et al. Therapeutic potential of fecal microbiota transplantation in colorectal cancer based on gut microbiota regulation: from pathogenesis to efficacy[J]. Therap Adv Gastroenterol, 2025, 18: 17562848251327167.
|
| [20] |
Lei W, Zhou K, Lei Y, et al. Gut microbiota shapes cancer immunotherapy responses[J]. NPJ Biofilms Microbiomes, 2025, 11(1): 143.
|
| [21] |
White MT, Sears CL. The microbial landscape of colorectal cancer[J]. Nat Rev Microbiol, 2024, 22(4): 240-254.
|
| [22] |
张校铭, 武永胜. 肠道菌群影响结直肠癌治疗的研究进展[J]. 现代医学与健康研究(电子版), 2024, 8(3): 28-31.
|
| [23] |
Gibson GR, Hutkins R, Sanders ME, et al. Expert consensus document: the international scientific association for probiotics and prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics[J]. Nat Rev Gastroenterol Hepatol, 2017, 14(8): 491-502.
|
| [24] |
Yang M, Wang L, Luo C, et al. Efficacy and safety of probiotics in preventing chemotherapy-related diarrhea in patients with colorectal cancer: a systematic review and meta-analysis based on 18 randomized trials[J]. Medicine (Baltimore), 2025, 104(27): e43126.
|
| [25] |
Kan HX, Cao Y, Ma Y, et al. Efficacy and safety of probiotics, prebiotics, and synbiotics for the prevention of colorectal cancer and precancerous lesion in high-risk populations: a systematic review and meta-analysis of randomized controlled trials[J]. J Dig Dis, 2024, 25(1): 14-26.
|
| [26] |
Flesch AT, Tonial ST, Contu PC, et al. Perioperative synbiotics administration decreases postoperative infections in patients with colorectal cancer: a randomized, double-blind clinical trial[J]. Rev Col Bras Cir, 2017, 44(6): 567-573.
|
| [27] |
Polakowski CB, Kato M, Preti VB, et al. Impact of the preoperative use of synbiotics in colorectal cancer patients: a prospective, randomized, double-blind, placebo-controlled study[J]. Nutrition, 2019, 58: 40-46.
|
| [28] |
Huang F, Li S, Chen W, et al. Postoperative probiotics administration attenuates gastrointestinal complications and gut microbiota dysbiosis caused by chemotherapy in colorectal cancer patients[J]. Nutrients, 2023, 15(2): 356.
|
| [29] |
宁新迈, 管鑫鑫, 李晓琴, 等. 肠道菌群参与结直肠癌免疫治疗的研究进展[J]. 现代中西医结合杂志, 2024, 33(24): 3486-3492.
|
| [30] |
Kim Y, Park SH, Cho B, et al. Fecal microbiota transplantation improves anti-PD-1 inhibitor efficacy in unresectable or metastatic solid cancers refractory to anti-PD-1 inhibitor[J]. Cell Host Microbe, 2024, 32(8): 1380-1393.
|
| [31] |
MD Anderson Cancer Center. Pilot trial of fecal microbiota transplantation and re-introduction of anti-PD-1 therapy in dMMR colorectal adenocarcinoma anti-PD-1 non-responders[DB/OL]. Bethesda (MD): ClinicalTrials.gov; 2020. Identifier: NCT04729322.
|
| [32] |
Kim Y, Kim G, Kim S, et al. Fecal microbiota transplantation improves anti-PD-1 inhibitor efficacy in unresectable or metastatic solid cancers refractory to anti-PD-1 inhibitor[J]. Cell Host & Microbe, 2024, 32(8): 1380-1393.e9.
|
| [33] |
Allegretti JR, Mullish BH, Kelly C, et al. The evolution of the use of faecal microbiota transplantation and emerging therapeutic indications[J]. Lancet, 2019, 394(10196): 420-431.
|
| [34] |
Lin A, Huang L, Jiang A, et al. Microbiota boost immunotherapy? A meta-analysis dives into fecal microbiota transplantation and immune checkpoint inhibitors[J]. BMC Med, 2025, 23(1): 341.
|
| [35] |
Gurbatri CR, Radford GA, Vrbanac L, et al. Engineering tumor-colonizing E. coli Nissle 1917 for detection and treatment of colorectal neoplasia[J]. Nat Commun, 2024, 15(1): 646.
|
| [36] |
Zhou T, Wu J, Tang H, et al. Enhancing tumor-specific recognition of programmable synthetic bacterial consortium for precision therapy of colorectal cancer[J]. NPJ Biofilms Microbiomes, 2024, 10(1): 6.
|
| [37] |
Chowdhury S, Castro S, Coker C, et al. Programmable bacteria induce durable tumor regression and systemic antitumor immunity[J]. Nat Med, 2019, 25(7): 1057-1063.
|
| [38] |
Luke JJ, Piha-Paul SA, Medina T, et al. Phase I study of SYNB1891, an engineered E. coli nissle strain expressing STING agonist, with and without Atezolizumab in advanced malignancies[J]. Clin Cancer Res, 2023, 29(13): 2435-2444.
|
| [39] |
Ishikawa H, Barber GN. STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling[J]. Nature, 2008, 455(7213): 674-678.
|
| [40] |
Dong X, Pan P, Zheng DW, et al. Bioinorganic hybrid bacteriophage for modulation of intestinal microbiota to remodel tumor-immune microenvironment against colorectal cancer[J]. Sci Adv, 2020, 6(20): eaba1590.
|
| [41] |
Liping Z, Sheng Y, Yinhang W, et al. Comprehensive retrospect and future perspective on bacteriophage and cancer[J]. Virol J, 2024, 21(1): 278.
|
| [42] |
Kenneth MJ, Chen JS, Fang CY, et al. Exploring the therapeutic potential of bacteriophage-mediated modulation of gut microbiota towards colorectal cancer[J]. Int J Antimicrob Agents, 2025, 66(5): 107585.
|
| [43] |
Chen X, Mendes BG, Alves BS, et al. Phage therapy in gut microbiome[J]. Prog Mol Biol Transl Sci, 2023, 201: 93-118.
|
| [44] |
Ternes D, Tsenkova M, Pozdeev VI, et al. The gut microbial metabolite formate exacerbates colorectal cancer progression[J]. Nat Metab, 2022, 4(4): 458-475.
|
| [45] |
Clarke J, Boussioutas A, Flanders B, et al. Can butyrate prevent colon cancer? The AusFAP study: a randomised, crossover clinical trial[J]. Contemp Clin Trials Commun, 2023, 32: 101092.
|
| [46] |
Cong J, Liu P, Han Z, et al. Bile acids modified by the intestinal microbiota promote colorectal cancer growth by suppressing CD8+T cell effector functions[J]. Immunity, 2024, 57(4): 876-889.
|
| [47] |
Jin WB, Xiao L, Jeong M, et al. Microbiota-derived bile acids antagonize the host androgen receptor and drive anti-tumor immunity[J]. Cell, 2025, 188(9): 2336-2353.
|
| [48] |
Wang L, Jiang W, Yang M, et al. Combination strategies of gut microbiota in cancer therapy through metabolic reprogramming and immune remodeling[J]. Cell Commun Signal, 2025, 23(1): 270.
|
| [49] |
Zhou M, Tang Y, Xu W, et al. Bacteria-based immunotherapy for cancer: a systematic review of preclinical studies[J]. Front Immunol, 2023, 14: 1140463.
|
| [50] |
李伟, 吴轲, 陶凯雄. 肠道菌群在胃肠道肿瘤发生发展及治疗中作用的现状与展望[J]. 中华实验外科杂志, 2021, 38(2): 199-204.
|
| [51] |
Wirbel J, Pyl PT, Kartal E, et al. Meta-analysis of fecal metagenomes reveals global microbial signatures that are specific for colorectal cancer[J]. Nat Med, 2019, 25(4): 679-689.
|
| [52] |
Cammarota G, Ianiro G, Kelly CR, et al. International consensus conference on stool banking for faecal microbiota transplantation in clinical practice[J]. Gut, 2019, 68(12): 2111-2121.
|
| [53] |
Mimee M, Nadeau P, Hayward A, et al. An ingestible bacterial–electronic system to monitor gastrointestinal health[J]. Science, 2018, 360(6391): 915-918.
|
| [54] |
Rynazal R, Fujisawa K, Shiroma H, et al. Leveraging explainable AI for gut microbiome-based colorectal cancer classification[J]. Genome Biol, 2023, 24(1): 21.
|
| [55] |
Dong X, Pan P, Zheng DW, et al. Bioinorganic hybrid bacteriophage for modulation of intestinal microbiota to remodel tumor-immune microenvironment against colorectal cancer[J]. Sci Adv, 2020, 6(20): eaba1590.
|